Get the Weekly Intelligence Brief — top committee picks every Sunday.
BFLY · NYSE · STOCK

Butterfly Network (BFLY) Stock Analysis

Healthcare Updated October 10, 2026
$8.24
52W $1.90 – $10.21
61/100
$2.20B
-28.5
2.04
AI Committee Verdict
Buy
61/100
Conviction: Moderate · 67% agreement · 6 analysts
+17.4%
-22.9%
0.76:1
Moderate
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is BFLY Bullish or Bearish?

Bullish. Innellis AI committee rates Butterfly Network, Inc. (BFLY) Buy with a composite score of 61/100 , based on 6 analysts with 67% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.02 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is sector concentration is already high (hhi 2796.97). The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
  • 3 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
  • ROE of only -38.4% -- cheap may mean cheap for a reason — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 34.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
61/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 28%
of 192 Healthcare peers
Value Analyst neutral
52 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -38.4% -- cheap may mean cheap for a reason
Growth Analyst bullish
67 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 28.1% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 34.4% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 10 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 61.0 to 61.0.

Analyst-level changes:
  • Risk Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
43.0
Neutral
MACD Histogram
-0.097
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$6.36
Resistance
$9.68
Bollinger %B
0.39
Inside Bands
Price vs Moving Averages
EMA 9
$8.55 Below
EMA 21
$8.54 Below
EMA 50
$8.24 Above
EMA 200
$6.24 Above

Fundamental Analysis

Valuation
33
Growth
42
Profitability
20
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -28.5×
P/B Ratio 11.42×
PEG Ratio 4.03
Dividend Yield 0.00%
52W High $10.21
52W Low $1.90
Quality & Growth
ROE -3932.3%
ROA -2598.8%
Gross Margin 5264.4%
Operating Margin -7078.7%
Revenue Growth YoY —
Debt / Equity 0.10
AI Fundamental Assessment
P/E ratio of -28.5 (inexpensive relative to a 15-40x range); Price-to-book of 11.4x; PEG ratio of 4.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -39.3%; Return on assets of -26.0%; Net margin of -66.7%; Gross margin of 52.6%; Current ratio of 4.06 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is negative (-0.11); Most recent quarter beat estimates by 14.8%; 3 consecutive earnings beats; EPS growth decelerating (+16.7% -> +0.0% QoQ); Analyst estimates rising over recent quarters
Get the Full BFLY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime